Még nem toboroz
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· 3. fázis· Hansoh BioMedical R&D Company· Forrás
Contact: Ding Ma, PhD
Toboroz
Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
NCT07840092· Tianjin Medical University Cancer Institute and Hospital· Forrás
Contact: Yang Liu, PhD.
Toboroz
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Contact: Liuchun Wang (principal investigator)
Toboroz
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· 2/3. fázis· Hoffmann-La Roche· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· 3. fázis· RemeGen Co., Ltd.· Forrás
Contact: Yongfeng Yang
Toboroz
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045· Alpha Biopharma (Jiangsu) Co., Ltd.· Forrás
Contact: Peng Chen Professor
Fut, nem toboroz
Prognostic Model of Elderly Hodgkin Lymphoma in China
NCT07374068· Tianjin Medical University Cancer Institute and Hospital· Forrás
Toboroz
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
NCT07162506· 2. fázis· Tianjin Medical University Cancer Institute and Hospital· Forrás
Contact: Wencheng Zhang, M.D.
Toboroz
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375· Hoffmann-La Roche· Forrás
Toboroz
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
NCT07038629· 2. fázis· Tianjin Medical University Cancer Institute and Hospital· Forrás
Contact: Wencheng Zhang, M.D.
Fut, nem toboroz
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· 3. fázis· Amgen· Forrás
Toboroz
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475· 1/2. fázis· Dizal Pharmaceuticals· Forrás
Contact: Prof. Huang
Toboroz
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049· 3. fázis· Evopoint Biosciences Inc.· Forrás
Contact: Yingjie zhao
Toboroz
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· 3. fázis· Akeso· Forrás
Contact: Dingzhi Huang, M.D.
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840· 2. fázis· Betta Pharmaceuticals Co., Ltd.· Forrás
Contact: Wanlin Chen, Master
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297· 2. fázis· Innovent Biologics (Suzhou) Co. Ltd.· Forrás
Toboroz
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· 3. fázis· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Forrás
Contact: Yehui Shi
Toboroz
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
NCT06704555· 2. fázis· Tianjin Medical University Cancer Institute and Hospital· Forrás
Contact: Huilai Zhang, MD,PhD
Toboroz
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324· 3. fázis· Nuvation Bio Inc.· Forrás
Contact: Peng Chen
Toboroz
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490· 1/2. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Hongli Li, Doctor
Toboroz
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357· 1/2. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
NCT06452602· 2. fázis· Tianjin Medical University Cancer Institute and Hospital· Forrás
Contact: Wen Cheng, M.D.
Toboroz
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994· 3. fázis· InnoCare Pharma Inc.· Forrás
Contact: Zhengzi Qian
Toboroz
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888· 2/3. fázis· Hutchmed· Forrás
Contact: Jihui Hao
Toboroz
Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer
NCT06241781· 2. fázis· Grit Biotechnology· Forrás
Contact: Ke Wang
Fut, nem toboroz
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· 3. fázis· Amgen· Forrás
Toboroz
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729· 2. fázis· Hansoh BioMedical R&D Company· Forrás
Contact: Siwei Bao
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· 3. fázis· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Forrás
Contact: Xuchen Cao
Toboroz
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
NCT06123754· 3. fázis· 3D Medicines (Sichuan) Co., Ltd.· Forrás
Contact: Changli Wang
Fut, nem toboroz
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841· 2. fázis· Shanghai Ming Ju Biotechnology Co., Ltd.· Forrás
Fut, nem toboroz
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910· Hoffmann-La Roche· Forrás
Toboroz
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT05994365· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Xiangqian Zheng, PhD
Fut, nem toboroz
Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study
NCT07491159· 1/2. fázis· Tianjin Medical University Cancer Institute and Hospital· Forrás
Toboroz
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
NCT05830500· 4. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Xiangqian Zheng, PhD
Toboroz
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123· 2. fázis· Hansoh BioMedical R&D Company· Forrás
Contact: Wei Guo, MD
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892· 3. fázis· Suzhou Puhe Pharmaceutical Technology Co., LTD· Forrás
Contact: Dingzhi Huang
Fut, nem toboroz
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of Daratumumab
NCT05438043· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366· 1/2. fázis· Genmab· Forrás
Toboroz
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270· 2. fázis· Beijing InnoCare Pharma Tech Co., Ltd.· Forrás
Contact: Wei Lu
Showing 50 of 66.